AKR1C1 and non-small cell lung carcinoma: Deacetylase SIRT2 could bind to AKR1C1 and revert the acetylation modification, and thus interrupts STAT3 signaling followed by its downstream transductions, ultimately suppressing the pro-metastatic function of AKR1C1 in NSCLC models (Figure 8).